These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 8671425)

  • 1. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin.
    Imthurn B; Macas E; Rosselli M; Keller PJ
    Hum Reprod; 1996 Nov; 11(11):2387-91. PubMed ID: 8981116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.
    Daya S; Gunby J; Hughes EG; Collins JA; Sagle MA
    Hum Reprod; 1995 Jun; 10(6):1392-6. PubMed ID: 7593503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.
    Westergaard LG; Yding Andersen C; Erb K; Laursen SB; Rasmussen PE; Rex S; Teisner B
    Reprod Biomed Online; 2004 Jan; 8(1):91-8. PubMed ID: 14759294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes.
    Kilani Z; Dakkak A; Ghunaim S; Cognigni GE; Tabarelli C; Parmegiani L; Filicori M
    Hum Reprod; 2003 Jun; 18(6):1194-9. PubMed ID: 12773445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women].
    Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z
    Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparative study on IVF outcomes with either purified FSH or human menopausal gonadotrophin in downregulated normogonadotrophic women.
    Ismail AF; Hesham AI; Salah Z; Khaled M; Fouad N; Ashraf N; Hatem S; Hamdi B
    Gynecol Obstet Invest; 2002; 53(4):220-3. PubMed ID: 12186987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.
    Westergaard LG; Laursen SB; Andersen CY
    Hum Reprod; 2000 May; 15(5):1003-8. PubMed ID: 10783342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone.
    Develioglu OH; Cox B; Toner JP; Oehninger S; Muasher SJ
    Hum Reprod; 1999 May; 14(5):1168-74. PubMed ID: 10325255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.